Today: September 26, 2018, 4:23 am
  
Business

MagForce AG Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

PR-Inside.com: 2018-02-10 11:56:01

MagForce AG Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

MagForce AG
Barbara von Frankenberg, +49-30-308380-77
Vice President
Communications & Investor Relations
E-Mail: bfrankenberg@magforce.com

MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announces that it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct a clinical trial with NanoTherm therapy as focal ablation treatment for intermediate risk prostate cancer.

The approval of this IDE now allows MagForce to conduct a pivotal clinical evaluation with the Company's innovative NanoTherm therapy at selected medical centers in the US. MagForce anticipates to initiate patient enrollment in this study in the coming months.

The purpose of this focal thermal ablation registration study that will enroll up to 120 men in a single arm study is to demonstrate that NanoTherm can focally ablate cancer lesions for patients who have advanced to intermediate risk prostate cancer stage and are under active surveillance. By focally ablating these cancer lesions, it is anticipated that patients will be able to be maintained in Active Surveillance Programs and to avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects.

Press Information


Published by
Hossam Abdel-Kader
+43 1 9582319
e-mail
http://www.pr-inside.com/


# 250 Words
Related Articles
More From The Author
BTV to Feature Glance in a Weekend [..]
VANCOUVER, British Columbia, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Glance Technologies Inc. (CSE:GET.CN) (CSE:GET.WT) (OTCQB:GLNNF) (FKT:GJT) [..]
FinGroup AG: Successful entry into the blockchain [..]
FinGroup AG (ISIN DE000A2DAMG0), a Munich-based Fintech company, is pleased to announce its successful entry into the blockchain and [..]
A.M. Best Comments on Credit Ratings of [..]
A.M. Best has commented that the Credit Ratings (ratings) of QBE Insurance Group Limited (QBE) (Australia) and its main insurance [..]
A.M. Best Downgrades Credit Ratings of ECICS [..]
A.M. Best has downgraded the Financial Strength Rating to B++ (Good) from A- (Excellent) and the Long-Term Issuer Credit Rating [..]
A.M. Best Affirms Credit Ratings of AzRe [..]
A.M. Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” of [..]
 
More From Business
Hurricane Damages Creating Extraordinary Demand for Heavy [..]
The effects of Hurricane Florence have been wide and far reaching, with 37 deaths and billions of dollars in damages [..]
Over 2,900 Took Part in 'In Style [..]
HONG KONG, Sept 21, 2018 - (ACN Newswire) - Major events under the "In Style, Hong Kong" mega promotion in [..]
RetailEX ASEAN 2018 Returns Bigger and Better
Brand-new zones, content rich conferences and cutting-edge retail technology innovation and solutions featured during the three-day [..]
Singapore's Senior Minister of State for Trade [..]
SINGAPORE, Sept 21, 2018 - (ACN Newswire) - Asian Downstream Summit is the anchor oil and gas event during Singapore [..]
Vanwise and Carwise Group Scoop Dealer Award
Vanwise & Carwise Group has won the prestigious award by CarGurus as ‘Top Rated Dealer 2018’ ● Dealer scoops prestigious [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.